Abbott Laboratories
ABT | NYSE
$107.45
-$1.07 (-0.99%)
At close: Nov 16, 2026, 4:02 PM ET
$106.76
-$0.69 (-0.64%)
After-hours:
Nov 16, 2026, 7:18 PM ET
Abbott Laboratories Company Profile
Company profile explainedCompany Profile
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Key Executives
| Name | Position |
|---|---|
| Robert Ford | Executive Chairman & CEO |
| Philip Boudreau | Chief Financial Officer & Executive Vice President of Finance |
| Sabina Ewing | Senior Vice President of Business & Technology Services and Chief Information Officer |
| Christopher J. Scoggins | Executive Vice President of Diabetes Care |
| Daniel Gesua Sive Salvadori | Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products |
| Elizabeth Cushman | Executive Vice President, General Counsel & Secretary |
| Erica L. Battaglia | Vice President and Chief Ethics & Compliance Officer |
| Lisa D. Earnhardt | Executive Vice President & Group President of Medical Devices |
| Melissa Brotz | Senior Vice President of Global Marketing & External Affairs |
| Michael Comilla | Vice President of Investor Relations. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 21, 2026 | 8-K | Current Report |
| Oct 21, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
Abbott Laboratories
| Country | United States |
| IPO Date | Mar 17, 1980 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 115,000 |
| CEO | Robert Ford |
Contact Details
100 Abbott Park Road Abbott Park,
Illinois 60064-6400 United States
Stock Details
| Ticker Symbol | ABT |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000001800 |
| CUSIP Number | 002824100 |
| ISIN Number | US0028241000 |
| SIC Code | 2834 |
Recent News
- 16 hours ago / zacks.comHere's How Abbott's EP Business Is Shaping Up for the Rest of 2026
- 18 hours ago / gurufocus.comIs ABT Overvalued? DCF Says Worth $76
- 3 days ago / zacks.comShould You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?
- 5 days ago / zacks.comIs Trending Stock Abbott Laboratories (ABT) a Buy Now?
- 5 days ago / zacks.comCan UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?
- 10 days ago / 247wallst.com3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years
- 13 days ago / marketwatch.comThese 12 stocks are good bets to beat the 10-year Treasury over the next decade
- 15 days ago / benzinga.comAbbott Touts Favorable Outcomes In Cardiovascular Device Trials
- 15 days ago / prnewswire.comLate-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- 15 days ago / gurufocus.comAbbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
Add to Watchlist
Select watchlists to add or remove ABT